BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 24092230)

  • 21. Three-phase 18F-fluorocholine PET/CT in the evaluation of prostate cancer recurrence.
    Steiner Ch; Vees H; Zaidi H; Wissmeyer M; Berrebi O; Kossovsky MP; Khan HG; Miralbell R; Ratib O; Buchegger F
    Nuklearmedizin; 2009; 48(1):1-9; quiz N2-3. PubMed ID: 19212605
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Operational characteristics of (11)c-choline positron emission tomography/computerized tomography for prostate cancer with biochemical recurrence after initial treatment.
    Mitchell CR; Lowe VJ; Rangel LJ; Hung JC; Kwon ED; Karnes RJ
    J Urol; 2013 Apr; 189(4):1308-13. PubMed ID: 23123372
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prognostic Value of [
    Cysouw M; Bouman-Wammes E; Hoekstra O; van den Eertwegh A; Piet M; van Moorselaar J; Boellaard R; Dahele M; Oprea-Lager D
    Int J Radiat Oncol Biol Phys; 2018 Jun; 101(2):406-410. PubMed ID: 29559285
    [TBL] [Abstract][Full Text] [Related]  

  • 24. No clinically relevant differences between positron emission tomography (PET) reconstructions based on low-dose or contrast-enhanced CT in combined integrated multiphase (18) F-Fluorethylcholine PET/CT for prostate cancer.
    Behrendt FF; Lensing C; Keil S; Mottaghy FM; Verburg FA
    J Med Imaging Radiat Oncol; 2016 Aug; 60(4):498-505. PubMed ID: 27297449
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Optimized protocol for (18)F-choline PET/CT in patients with biochemically relapsed prostate cancer: experiences on 250 consecutive cases.
    Chondrogiannis S; Marzola MC; Grassetto G; Rampin L; Massaro A; Colletti PM; Rubello D
    Clin Nucl Med; 2015 Jun; 40(6):e308-12. PubMed ID: 25742236
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [PET/CT with (11)C-choline and (18)F-FDG in patients with elevated PSA after radical treatment of a prostate cancer].
    García JR; Soler M; Blanch MA; Ramírez I; Riera E; Lozano P; Pérez X; Delgado E; Carrio I; Lomeña F
    Rev Esp Med Nucl; 2009; 28(3):95-100. PubMed ID: 19558948
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Role of 11C-choline PET/CT in the re-staging of prostate cancer patients with biochemical relapse and negative results at bone scintigraphy.
    Fuccio C; Castellucci P; Schiavina R; Guidalotti PL; Gavaruzzi G; Montini GC; Nanni C; Marzola MC; Rubello D; Fanti S
    Eur J Radiol; 2012 Aug; 81(8):e893-6. PubMed ID: 22621862
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Spine metastases in prostate cancer: comparison of technetium-99m-MDP whole-body bone scintigraphy, [(18) F]choline positron emission tomography(PET)/computed tomography (CT) and [(18) F]NaF PET/CT.
    Poulsen MH; Petersen H; Høilund-Carlsen PF; Jakobsen JS; Gerke O; Karstoft J; Steffansen SI; Walter S
    BJU Int; 2014 Dec; 114(6):818-23. PubMed ID: 24314065
    [TBL] [Abstract][Full Text] [Related]  

  • 29. 11C-choline PET/CT predicts prostate cancer-specific survival in patients with biochemical failure during androgen-deprivation therapy.
    Giovacchini G; Picchio M; Garcia-Parra R; Briganti A; Abdollah F; Gianolli L; Schindler C; Montorsi F; Messa C; Fazio F
    J Nucl Med; 2014 Feb; 55(2):233-41. PubMed ID: 24408897
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Role of choline PET/CT in guiding target volume delineation for irradiation of prostate cancer.
    Schwarzenböck SM; Kurth J; Gocke Ch; Kuhnt T; Hildebrandt G; Krause BJ
    Eur J Nucl Med Mol Imaging; 2013 Jul; 40 Suppl 1():S28-35. PubMed ID: 23576101
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical evaluation of a block sequential regularized expectation maximization reconstruction algorithm in 18F-FDG PET/CT studies.
    Sah BR; Stolzmann P; Delso G; Wollenweber SD; Hüllner M; Hakami YA; Queiroz MA; Barbosa FG; von Schulthess GK; Pietsch C; Veit-Haibach P
    Nucl Med Commun; 2017 Jan; 38(1):57-66. PubMed ID: 27755394
    [TBL] [Abstract][Full Text] [Related]  

  • 32. 18F choline PET/CT in the preoperative staging of prostate cancer in patients with intermediate or high risk of extracapsular disease: a prospective study of 130 patients.
    Beheshti M; Imamovic L; Broinger G; Vali R; Waldenberger P; Stoiber F; Nader M; Gruy B; Janetschek G; Langsteger W
    Radiology; 2010 Mar; 254(3):925-33. PubMed ID: 20177103
    [TBL] [Abstract][Full Text] [Related]  

  • 33. PET/MR imaging in the detection and characterization of pulmonary lesions: technical and diagnostic evaluation in comparison to PET/CT.
    Rauscher I; Eiber M; Fürst S; Souvatzoglou M; Nekolla SG; Ziegler SI; Rummeny EJ; Schwaiger M; Beer AJ
    J Nucl Med; 2014 May; 55(5):724-9. PubMed ID: 24652827
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Diagnosis of metastases from postoperative differentiated thyroid cancer: comparison between FDG and FLT PET/CT studies.
    Nakajo M; Nakajo M; Jinguji M; Tani A; Kajiya Y; Tanabe H; Fukukura Y; Nakabeppu Y; Koriyama C
    Radiology; 2013 Jun; 267(3):891-901. PubMed ID: 23468571
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Repeatability of Quantitative 18F-Fluoromethylcholine PET/CT Studies in Prostate Cancer.
    Oprea-Lager DE; Kramer G; van de Ven PM; van den Eertwegh AJ; van Moorselaar RJ; Schober P; Hoekstra OS; Lammertsma AA; Boellaard R
    J Nucl Med; 2016 May; 57(5):721-7. PubMed ID: 26697964
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Lesion Detection and Interobserver Agreement with Advanced Image Reconstruction for
    Jansen BHE; Jansen RW; Wondergem M; Srbljin S; de Klerk JMH; Lissenberg-Witte BI; Vis AN; van Moorselaar RJA; Boellaard R; Hoekstra OS; Oprea-Lager DE
    J Nucl Med; 2020 Feb; 61(2):210-216. PubMed ID: 31481580
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Role of 11C-choline PET/CT in the restaging of prostate cancer patients showing a single lesion on bone scintigraphy.
    Fuccio C; Castellucci P; Schiavina R; Santi I; Allegri V; Pettinato V; Boschi S; Martorana G; Al-Nahhas A; Rubello D; Fanti S
    Ann Nucl Med; 2010 Jul; 24(6):485-92. PubMed ID: 20544323
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [11C]choline positron emission tomography/computerized tomography to restage prostate cancer cases with biochemical failure after radical prostatectomy and no disease evidence on conventional imaging.
    Giovacchini G; Picchio M; Briganti A; Cozzarini C; Scattoni V; Salonia A; Landoni C; Gianolli L; Di Muzio N; Rigatti P; Montorsi F; Messa C
    J Urol; 2010 Sep; 184(3):938-43. PubMed ID: 20643445
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Is there an additional value of ¹¹C-choline PET-CT to T2-weighted MRI images in the localization of intraprostatic tumor nodules?
    Van den Bergh L; Koole M; Isebaert S; Joniau S; Deroose CM; Oyen R; Lerut E; Budiharto T; Mottaghy F; Bormans G; Van Poppel H; Haustermans K
    Int J Radiat Oncol Biol Phys; 2012 Aug; 83(5):1486-92. PubMed ID: 22284686
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Spectrum of metastatic and nonmetastatic skeletal findings with dual-phase 18F-FECH PET/CT in patients with biochemical relapse of prostate cancer.
    Haroon A; Syed R; Endozo R; Allie R; Freeman A; Emberton M; Bomanji J
    Nucl Med Commun; 2017 May; 38(5):407-414. PubMed ID: 28379896
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.